BOCCACCINO, ALESSANDRA
 Distribuzione geografica
Continente #
NA - Nord America 529
EU - Europa 298
AS - Asia 80
AF - Africa 32
SA - Sud America 1
Totale 940
Nazione #
US - Stati Uniti d'America 526
IT - Italia 154
SE - Svezia 55
SG - Singapore 38
BG - Bulgaria 25
GB - Regno Unito 23
CN - Cina 21
CI - Costa d'Avorio 20
DE - Germania 16
VN - Vietnam 10
PL - Polonia 9
FR - Francia 7
NG - Nigeria 7
HK - Hong Kong 6
SN - Senegal 4
CA - Canada 3
ES - Italia 3
RU - Federazione Russa 3
IN - India 2
AT - Austria 1
CL - Cile 1
CZ - Repubblica Ceca 1
EG - Egitto 1
IL - Israele 1
KH - Cambogia 1
MY - Malesia 1
UA - Ucraina 1
Totale 940
Città #
Chandler 76
Fairfield 67
Ashburn 38
Wilmington 37
New York 34
Florence 33
Seattle 32
Cambridge 27
Sofia 25
Woodbridge 22
Abidjan 20
London 16
Princeton 16
Lawrence 15
Ogden 14
Genoa 13
Pisa 13
Bremen 12
Medford 12
Serra 10
Rome 9
Warsaw 9
Ann Arbor 8
Houston 8
Lagos 7
Los Angeles 7
Milan 6
San Diego 6
Verona 6
Kent 5
Seacroft 5
Beijing 4
Dakar 4
Hong Kong 4
Phoenix 4
Polverigi 4
Redwood City 4
Turin 4
Singapore 3
Washington 3
Anzio 2
Bari 2
Des Moines 2
Dong Ket 2
Fano 2
Moscow 2
Nanchang 2
Nanjing 2
Norwalk 2
Noventa di Piave 2
Ottawa 2
Pistoia 2
San Giuliano Terme 2
Santa Maria A Monte 2
Shanghai 2
Vitry-sur-seine 2
Barcelona 1
Bellinzago Novarese 1
Berlin 1
Berlingo 1
Buffalo 1
Cairo 1
Castiglione Chiavarese 1
Catania 1
Central 1
Città della Pieve 1
Cologne 1
Dearborn 1
Fiumefreddo Di Sicilia 1
Frattamaggiore 1
Guangzhou 1
Hanoi 1
Hebei 1
Indore 1
Kowloon 1
Kuala Lumpur 1
Kunming 1
Kyiv 1
Marseille 1
Montefalco 1
Nagold 1
Perugia 1
Phnom Penh 1
Pierrefonds 1
Pune 1
Rozzano 1
Sant Joan Despí 1
Saratov 1
Tappahannock 1
Tel Aviv 1
Torrevecchia Pia 1
Trieste 1
Uzzano 1
Venice 1
Vienna 1
Totale 713
Nome #
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 105
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 94
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 86
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies 68
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 61
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 56
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 55
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 44
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest 43
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 43
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies 38
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 36
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 35
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study 35
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 28
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 28
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 22
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 19
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 18
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 18
null 15
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study 14
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 12
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO 7
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 4
Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset 1
Totale 985
Categoria #
all - tutte 4.262
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.262


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201913 0 0 0 0 0 0 0 0 0 0 9 4
2019/2020141 9 11 9 9 21 16 18 15 14 9 9 1
2020/2021117 3 2 3 6 1 42 2 6 13 5 12 22
2021/2022124 1 0 2 0 17 23 2 5 4 16 15 39
2022/2023320 23 47 19 23 30 31 17 20 51 2 48 9
2023/2024258 11 24 36 32 32 37 16 14 5 13 38 0
Totale 985